Results 21 to 30 of about 10,843 (242)

Solubility and thermodynamic study of deferiprone in propylene glycol and ethanol mixture

BMC Chemistry, 2023
This work aims to obtain the solubility, density and thermodynamic parameters of deferiprone in propylene glycol and ethanol. For this purpose, a shake-flask technique was applied for solid–liquid equilibration and the spectrophotometry method was ...
Samira Radmand, Homa Rezaei, Hongkun Zhao, E. Rahimpour, A. Jouyban   +4 more
semanticscholar   +1 more source

Effect of Deferiprone versus Deferiprone with Deferasirox in Iron Chelation Therapy of Thalassemia Children

Journal of Medical Science And clinical Research, 2018
Dr Syeda Jarka Jahir
openalex   +2 more sources

Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study

Pediatric Blood & Cancer, 2023
Children with sickle cell disease (SCD) who are chronically transfused often, require iron chelation therapy. There are limited data that allow for comparison of the efficacy and safety of the iron chelator deferiprone versus deferoxamine in children ...
Mona Hamdy, A. El-Beshlawy, Mônica P A Veríssimo, J. Kanter, B. Inusa, S. Williams, David Lee, N. Temin, C. Fradette, F. Tricta, F. Ebeid, J. Kwiatkowski, M. Elalfy   +12 more
semanticscholar   +1 more source

Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve

Scientific Reports, 2022
Multiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal demyelination in the brain and spinal cord. Studies showed that iron released during the course of myelin breakdown exacerbates tissue damage, which is in agreement with the ...
Atefeh Rayatpour, F. Foolad, Motahare Heibatollahi, K. Khajeh, Mohammad Javan   +4 more
semanticscholar   +1 more source

Deferiprone for the treatment of Friedreich's ataxia [PDF]

Journal of Neurochemistry, 2013
AbstractFriedreich's ataxia (FRDA) is a neurological disease related to a deficiency of the protein frataxin involved in iron–sulfur (Fe–S) cluster biogenesis. This leads to an increased cellular iron uptake accumulating in mitochondria, and a subsequently disturbed iron homeostasis.
Pandolfo, Massimo, Hausmann, Laura
openaire   +3 more sources

Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial [PDF]

, 2014
Blood transfusion and iron chelation currently represent a supportive therapy to manage anemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease.
Giusi Calvaruso, Angela Vitrano, Rosario Di Maggio, Samir K. Ballas, Martin H. Steinberg, Paolo Rigano, Massimiliano Sacco, Paul Telfer, Disma Renda, Rita Barone, Aurelio Maggio   +10 more
openalex   +4 more sources

Iron-loaded deferiprone can support full hemoglobinization of cultured red blood cells

Scientific Reports, 2023
Iron, supplemented as iron-loaded transferrin (holotransferrin), is an essential nutrient in mammalian cell cultures, particularly for erythroid cultures.
Joan Sebastián Gallego-Murillo, N. Yağcı, Eduardo Machado Pinho, Sebastian Aljoscha Wahl, E. van den Akker, M. von Lindern   +5 more
semanticscholar   +1 more source

Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia [PDF]

, 2013
Copyright @ 2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Filla, A Ramazzotti, A Saveliev, AH Koeppen, AH Koeppen, AL Bulteau, Annalisa Pastore, B Tomassini, C la Porte, C Sandi, C Xu, CG Wermuth, Chiranjeevi Sandi, D Beher, D Herman, D Marmolino, D Marmolino, E Grabczyk, E Grabczyk, E Greene, E Lesuisse, E Monros, E Soragni, F Foury, F Picard, F Sacca, G Coppola, G De Michele, H Dai, H Puccio, H Ulukan, I Castaldo, JA Baur, JA Baur, JB Schulz, JG Wood, JH Willis, Joseph P. Sarsero, JP Sarsero, JP Sarsero, JP Sarsero, JT Rodgers, K Narayanan, K Ohshima, KA O’Hagan, KT Howitz, L Almeida, L Pirola, L Santoro, Lingli Li, Lucille Voullaire, M Ghazizadeh, M Iyer, M Mokni, M Pandolfo, M Pandolfo, M Rai, M Rai, Mark A. Pook, Martin B. Delatycki, MB Delatycki, MB Delatycki, MV Evans-Galea, N Boddaert, N Puspasari, N Sakamoto, P Cavadini, P Cavadini, P Corish, Panos A. Ioannou, Q Wang, S Al-Mahdawi, S Al-Mahdawi, S Al-Mahdawi, S Boesch, S Park, SI Bidichandani, T Boulikas, T Walle, T Wang, T Yang, T Yoon, T Yoon, V Cucciolla, YS Sohn   +84 more
core   +5 more sources

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years

Blood Advances, 2022
Key Points • Long-term deferiprone therapy was not associated with new safety concerns in patients with SCD or other anemias.• Long-term deferiprone therapy led to continued and progressive reduction in iron load in patients with SCD or other anemias.
Mohsen Saleh Elalfy, M. Hamdy, A. El Beshlawy, F. Ebeid, Mohammed Badr, J. Kanter, B. Inusa, A. Adly, S. Williams, Y. Kilinç, David Lee, C. Fradette, A. Rozova, Noemi Toiber Temin, F. Tricta, J. Kwiatkowski   +15 more
semanticscholar   +1 more source

Successful private–public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines [PDF]

, 2014
The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children.
Baiardi, P, Bonifazi, D, Bonifazi, F, Ceci, A, Chiron, C, Davies, E H, Eichler, I, Felisi, M, Giannuzzi, V, Giaquinto, C, Jacqz-Aigrain, E, Neubert, A, on behalf of the GRiP Consortium,, Pressler, R, Rabe, H, Ruggieri, L, Turner, M A, Whitaker, M J   +17 more
core   +1 more source